Clinical Trials
GCCL, Medicover Sign MOU for Clinical Trial Services Expansion
GCCL Co., Ltd. (GCCL) and Medicover Integrated Clinical Services (MICS), a division of Medicover, have entered into a Memorandum of Understanding (MOU) aimed at advancing multinational clinical trial services. The agreement brings together GCCL, a data-driven clinical trial services...
Business & Industry
Novartis Breaks Ground on San Diego Biomedical R&D Site
Novartis has started work on a $1.1 billion biomedical research facility in California, adding a major new pillar to its long-term US investment strategy. The San Diego biomedical R&D site is part of a wider $23 billion expansion programme...
Business & Industry
Bristol Myers Evinova Partnership Targets AI-Led Trials
Bristol Myers Squibb has entered a global agreement with Evinova to deploy AI-powered clinical development tools across its worldwide pipeline. The Bristol Myers Evinova partnership is designed to improve trial efficiency, reduce costs and support better decision-making throughout drug...
Business & Industry
Lilly Buys Orna for $2.4bn to Advance In Vivo Therapies
Eli Lilly has agreed to acquire in vivo CAR-T developer Orna Therapeutics in a deal worth up to $2.4 billion, marking another rapid move to strengthen its research pipeline. The transaction positions Lilly buys Orna for $2.4bn as a...
Clinical Trials
Study Finds Fenebrutinib Cuts Disability Progression In PPMS
Roche announced late-breaking Phase III data showing that fenebrutinib reduces disability progression in PPMS, marking the first investigational advance for primary progressive multiple sclerosis in more than a decade. Results from the FENtrepid study showed the Bruton’s tyrosine kinase...
Business & Industry
Innovent-Lilly Partnership Expands Global Drug Development
Innovent Biologics has announced a strategic Innovent-Lilly partnership with Eli Lilly and Company to advance the global development of new medicines in oncology and immunology. The agreement represents the seventh partnership between the two companies and introduces a new...
Business & Industry
GSK Targets Faster Drug Development, Selective Acquisitions
GSK’s new chief executive, Luke Miels, said the drugmaker will prioritise faster drug development as it enters its next phase of growth, with a tighter focus on programmes that can change standards of care and selective bolt-on acquisitions. Miels,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















